Management group changes in Episurf Medical
Ladan Amiri, Head of Quality and Regulatory Affairs at Episurf Medical, has decided to pursue other opportunities outside the company. Ladan Amiri will be replaced by Katarina Flodström, PhD, currently Research Scientist at Episurf Medical and responsible for Episurf Medical’s US project. Katarina Flodström will assume the position as Chief Regulatory Officer with responsibility for regulatory affairs, quality affairs and intellectual property, and will take part in the company’s management group. The change will be effective as of June 1, 2018.
“Ladan has been with Episurf Medical since 2015 and she has played an important role in an intense period in the company’s development. Ladan has been a great team member and we wish her the best of luck in the future. At the same time, I am very pleased with the appointment of Katarina Flodström as Chief Regulatory Officer” says Pål Ryfors, CEO Episurf Medical.
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalised treatment alternatives. Episurf Medical’s Episealer® personalised implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.50 CEST on 14 May 2018.
Tags: